Live feed/
Filings
/
SCHEDULE 13D
/
0001193125-26-432028
Stake: 25.60%
Shares: 13,692,507
CUSIP: 178782108
Class: Common Stock, $0.0001 par value
Composite Decision Signal · PASS (LOW BASE-RATE EDGE)
Conviction Score: 22/100 · Filer 90d Win Rate: 0% · Hist. 90d Edge: -5.2%
- Active Schedule 13D filer baseline
- High conviction ownership stake (25.6%)
Item 4 — Purpose of Transaction
AVF XII and the other Reporting Persons acquired the Common Stock for investment purposes. Depending on market conditions, the continuing evaluation of the business and prospects of the Issuer and other factors, AVF XII and other Reporting Persons may dispose of or acquire additional shares of Common Stock of the Issuer. Except as set forth above, none of the Reporting Persons has any present plans which relate to or would result in the matters set forth in subparagraphs (a) - (j) of Item 4 of Schedule 13D.
Cross-References
Insider Activity (last 365d)
0 transactions
0 buys · 0 sales · 0 awards/exercises
Issuer Cluster
2 13D/G filings on this issuer
1 other filing besides this one
Filer Track Record
3 filings by this filer
2 other filings in the data moat
Short Interest
—
Not in latest FINRA snapshot
Other 13D/G Filings on City Therapeutics, Inc.
| Filed | Form | Filer | Stake | Shares | |
|---|
| 2026-10-22 |
SCHEDULE 13G |
Invus Global Management, LLC |
— |
— |
view → |
Other Filings by ARCH Venture Fund XII, L.P.
| Filed | Form | Issuer | Stake | Shares | |
|---|
| 2026-04-01 |
SCHEDULE 13D/A |
Neumora Therapeutics, Inc. NMRA |
18.70% |
33,847,838 |
view → |
| 2025-08-11 |
SCHEDULE |
Prime Medicine, Inc. PRME |
10.40% |
18,587,036 |
view → |
Want this depth on every filing the moment it hits SEC EDGAR?
Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.
See pricing →